The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
March 31st 2025
The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.
IO-TKI Combinations Have Potential as Preferred First-line mRCC Therapy
Murine Study Suggests Novel I-O Combo May Be Effective in CRC